CDK8作为治疗标,用于预测宫平细胞癌 (CESC) 的整体存活率
Feiting Xie1, Qiugang Zhu2, Shizhou Yang1,3,4
1Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Women's Hospital, Zhejiang University School of Medicine, China.
Current cancer drug targets
|January 27, 2025
概括
循环素依赖性激酶8 (CDK8) 在宫平细胞癌 (CESC) 中过度表达,影响患者的存活率. 在CESC瘤中,CDK8高甲基化与更好的生存率和免疫细胞透相关.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 循环素依赖酶8 (CDK8) 是一种转录调节剂,参与细胞过程.
- CDK8与介质复合体子单元MED12,MED13和环林C相互作用.
- 了解CDK8在椎状细胞癌 (CESC) 中的作用对于临床应用至关重要.
研究的目的:
- 在CESC中调查CDK8表达和预后之间的关联.
- 探索CDK8甲基化状态与患者存活率之间的关系.
- 在CESC中检查CDK8和免疫细胞透之间的联系.
主要方法:
- 在CESC组织中分析CDK8表达水平.
- 评估CDK8甲基化状态及其与患者生存数据的相关性.
- 评估CDK8与瘤微环境中的免疫细胞透的关联.
主要成果:
- 发现CDK8在CESC中过度表达.
- 与低甲基化患者相比,CDK8高甲基化患者的生存率更高.
- CDK8表达水平与CESC瘤内的免疫细胞透有显著的关联.
结论:
- 过度表达CDK8与CESC的预后不佳有关.
- CDK8甲基化状态作为预测患者生存的潜在生物标志物.
- CDK8影响CESC中的瘤免疫微环境,提供治疗点.
关键词:
CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK9 CDK8 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9CESC CESC 的意思是" CESC"的意思.诊断 诊断 诊断 诊断 诊断 诊断免疫细胞的透.甲基化处理 甲基化处理预测预后预后的预测.更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
10:09Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.2K
相关概念视频
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
